Vendors' role in single-use plant design could cut costs, says M+W

By Dan Stanton contact

- Last updated on GMT

Vendors' role in single-use plant design could cut costs, says M+W
Single-use vendors could help cut costs in designing and building biopharma facilities, according to engineering firm M+W.

At last month’s Bioprocess International convention in Boston​, some end users - including Pfizer and Merck - expressed their concerns about the growing reliance on systems vendors in the supply chain, especially as the industry continues shifting towards single-use.

Kurt Gilson, Western Regional Manager at Total Facility Solutions (TFS) – a subsidiary of architectural, engineering, and construction management firm M+W – believes these fears are unfounded and if vendors take a more active role in facility design then this could lead to greater flexibility and reduced costs.

The use of disposable or single-use technology is dramatically changing plant design and construction,”​ he told Biopharma-Reporter.com.

“If the bioprocess manufacturing requirements align with the technology capabilities of the systems vendor, then the detailed design and construction of the plant by a systems vendor does not limit the plant flexibility any more than traditional delivery methods, and could offer schedule and cost advantages.”

In TFS’s experience, equipment manufacturers do not typically design and build bioprocess facilities he continued. “They are typically a key contributor to the bioprocess engineering, but few vendors have the breadth of process technology to deliver complete systems including support utilities and cleanrooms.”

However, one vendor, Sartorius Stedim Biotech, recently received an award for the design of WuXi Apptech’s fully disposable biomanufacturing facility in China, with spokesperson Miriam Monge telling this publication​ the advent of single-use was making such a design/supply client relationship possible.

Similarly, supplier of bioprocessing systems GE Healthcare is designing and building a modular biopharmaceutical facility​ on behalf of JHL Biotech, also in China.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars